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Abstract
Background: Chronic hepatitis B virus (HBV) infection is associated with
hepatocellular carcinoma (HCC), and speciﬁc viral factors have been identiﬁed
that may increase the risk for HCC development. However, the differences in these
viral factors in chronic carriers who seldom develop HCC compared with HCC
patients have not been adequately evaluated. Methods: From 1989 to 2005, 101
hepatitis B surface antigen-positive patients presented to our clinic with HCC.
Baseline basal core promoter (BCP) T1762/A1764 mutants, precore (PC) A1896
mutants, HBV genotypes and HBV DNA in HCC patients were compared with 67
chronic carriers who had been followed for a mean of 112.177.7 standard
deviation months. Results: At baseline, HCC patients had lower levels of serum
albumin, but higher values of alkaline phosphatase, aspartate aminotransferase,
alanine aminotransferase, bilirubin and a-foetoprotein than those of chronic
carriers (Po0.001 for all comparisons). The presence of genotype C, higher
frequencies of PC A1896 mutants, BCP T1762/A1764 mutants and higher
circulating levels of HBV DNA were more frequently detected in HCC patients
than that in chronic carriers (Po0.001 for all observations). Logistic regression
analysis revealed that BCP T1762/A1764 mutants [odds ratio (OR) 11.14, 95%
conﬁdence interval (CI) 3.05–40.72; Po0.001] and PC A1896 mutants (OR 3.75,
95% CI 1.14–12.34; Po0.05) were signiﬁcantly associated with HCC develop-
ment. Conclusion: Our results indicate that the presence of BCPand PC mutations
signiﬁcantly increases the risk for HCC in chronic hepatitis B patients. These
mutations were less often detected in chronic carriers who seldom develop HCC.
Hepatocellular carcinoma (HCC) is a common malig-
nancy in many areas of the world (1). The largest
concentrations of HCC cases are in Asia and in Africa,
where over 80% of liver cancer cases are reported. In
thesecountries, the most important aetiology for HCC
is chronic hepatitis B virus (HBV) infection, and
strong geographical correlations have been reported
between the incidence of HCC and the prevalence of
HBV infections in these areas.
The development of chronic HBV infection is
dependent on the age of HBVexposure. Up to 90% of
infants born to hepatitis B surface antigen (HBsAg)-
positive and hepatitis B e antigen (HBeAg)-positive
mothers, and 5–10% of adults with acute HBV infec-
tion progress to chronic hepatitis B. Thereafter, it is
estimated that 15–40% of chronic hepatitis B patients
will progress to cirrhosis and to HCC (2). This
indicates that 60–85% of HBsAg-positive carriers will
have a benign outcome and may remain as inactive
carriers with no progression of liver disease. Thus, it is
important to identify HBV-infected patients who are
at a higher risk for disease progression from those who
will not develop decompensated liver disease or HCC.
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
exploitation.
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titis B infection progress to HCC are unknown. Host
factors such as an immune response to HBV, a genetic
predisposition to HCC development, high HBV repli-
cation rates, as well as mutations within the HBV
genome have been related to HCC development.
A dual mutation in the basal core promoter (BCP)
region of the HBV genome involving an A–Tsubstitu-
tion at nucleotide 1762 and a G–A substitution at
nucleotide 1764 has been associated with HCC devel-
opment (3–5). Also, a mutation in the precore (PC)
region of the HBV genome involving a G–A substitu-
tion at nucleotide 1896 has been described in patients
with HBeAg-negative chronic hepatitis (6). However,
its role in HCC pathogenesis is not well established.
Studies from Asia have indicated that patients with
genotype C are at a higher risk for HCC than patients
with other genotypes (7–10). Also, genotype B has
been implicated in a younger population of HCC in
Taiwan, but in older HCC patients in Japan (7, 8, 11,
12). Recently, elevated serum levels of HBV DNA have
been noted to increase the risk for HCC (13–15).
In the present report, we compared the baseline
hepatitis B virological proﬁles of 67 chronic carriers who
had been followed for a mean of 9 years with no liver
complications with 101 HCC patients who were referred
to our Liver Center. Our aimwasto identifydifferencesin
the BCP and PC mutations, HBV genotypes and baseline
HBV DNA levels between these two groups of patients
who had signiﬁcantly different clinical outcomes.
Methods
Patients
From January 1989 to June 2005, 101 patients with
HBsAg-positive HCC were referred to our Liver Center
in Pasadena, CA, USA. The diagnosis of HCC was
conﬁrmed by biopsy of the mass lesion in the liver, and
by typical computed tomographyormagnetic resonance
imaging ﬁndings for HCC along with a-foetoprotein
(AFP) serum levels of Z20ng/mL. Also, from January
1989 to December 1998, 110 HBsAg-positive patients
who were classiﬁed as chronic carriers were enrolled in a
prospective study (16). At presentation, these chronic
carriers had no symptoms or signs of chronic liver
disease, and had normal liver tests and normal platelet
counts. These chronic carriers visited our clinic every
6–12 months and had persistently normal liver tests.
During a mean follow-up of 112.177.7 standard
deviation (SD) months, none had progression of liver
disease or HCC development. In order to conform to
the standard deﬁnition of a chronic carrier (17–19), we
selected from this group of patients only those who were
HBeAg negative, anti-HBe positive, had persistently
normal serum aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels and had baseline
serum HBV DNA levels of  10
5copies/mL that were
measured in one laboratory in 2005 as described below.
Sixty-seven of the original 110 patients ﬁt the standard
criteria for a chronic carrier, and they were used for
comparison with the HCC patients. In these chronic
carriers, 63 had baseline HBV DNA values of
o100000copies/mL while four patients had HBV
DNA levels of 141000, 150000, 160000 and 335000co-
pies/mL respectively. For both chroniccarriers and HCC
patients, a serum sample was drawn during the initial
visit and stored at 701 until use.
Laboratory tests
During the initial visit, measurements of serum albu-
min, AST, ALT, total bilirubin, alkaline phosphatase,
platelet counts and AFP levels were obtained from 101
HCC patients and from 67 chronic carriers. HBeAg
and anti-HBe were measured with commercially avail-
able kits (Abbott Laboratories, North Chicago, IL,
USA). In 2005, we collaborated with the Hepatitis
Research Center at National Taiwan University Hospi-
tal in Taipei, Taiwan, and stored serum samples from
the 101 HCC patients, and 67 chronic carriers were
sent for analysis of BCP mutants, PC mutants, HBV
genotypes and HBV DNA.
Serum HBV DNA was quantiﬁed by a real-time
polymerase chain reaction assay in the linear range
from 10
2 to 10
11copies/mL (20). For reporting pur-
poses, the HBV DNA values were log10 transformed.
The identiﬁcation of HBV genotypes was performed by
melting curve analysis (20), and supplemented by
direct sequencing of the pre-S amplicon and phyloge-
netic analysis by comparing the nucleotide sequence
with 33 reference HBV strains obtained from GenBank
as described previously (21). Ampliﬁcation and
sequencing of PC (nucleotides 1814–1900) and BCP
(nucleotides 1742–1849) genes were performed as
described (5, 7). The nucleotide sequences of the
ampliﬁed products were directly determined using
ﬂuorescence-labelled primers with a 3100 Automatic
Sequencer (Applied Biosystems, Foster City, CA, USA).
Sequencing conditions were speciﬁed in the protocol
for the TaqDyeDeoxy Terminator Cycle SequencingKit
(Applied Biosystems). The inner primer pair was used
as sequencing primers for both directions of the gene.
Statistical analysis
We investigated the distribution of different baseline
characteristics by HCC status. All continuous variables
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dent’s t-test. In case of a non-normal distribution, the
data were normalized with log transformation before
t-tests. Categorical data were compared using w
2 tests.
Initially, we performed w
2 tests to investigate the
relationship between the possible risk factors of HCC,
i.e. genotype C infection, BCP T1762/A1764 and PC
A1896 gene mutations. Both BCP and PC mutations
were coded as dominant. We then ﬁtted a logistic
regressionmodelforeachofthose potentialriskfactors,
adjusting for age, sex and race (partially adjusted
model). The possible confounding effect between the
risk factors was evaluated by ﬁtting logistic models with
any combination of the two risk factors and noting
more than a 10% change in the odds ratios (OR)
compared with the single risk factor models. Effect
modiﬁcations between the risk factors were evaluated
by ﬁtting models with proper interaction terms and
performing likelihood ratio tests between the partial
(modelwith the main effectof variables of interest) and
full model (modelwith the maineffectof bothvariables
as well as the proper interaction term). The fully
adjusted model for HCC selected was based on the
factors identiﬁed in the process described above and by
comparing different models using Akaike information
criterion (AIC) (22). The lowest AIC identiﬁed the best
model. All analysis was performed using SAS 9.1.
Results
Patients and laboratory tests
At presentation, the mean age of the HCC patients was
older than the chronic carriers (53.313.5 vs.
45.412.3 years, P=0.002), and more HCC patients
were males (83.2 vs. 43.3%, Po0.0001; Table 1). The
HCC patients had signiﬁcantly lower baseline mean
serum albumin values but higher AST, ALT, alkaline
phosphatase and total bilirubin levels than chronic
carriers (Po0.0001 for all observations). Also, the
mean serum AFP values were signiﬁcantly higher in
HCC patients than in chronic carriers (P=0.0001).
Hepatitis B virological tests
Patients with HCC had a higher prevalence of geno-
type C than chronic carriers (68.1 vs. 34.2%,
P=0.0003), while genotype B was more frequently
detected in chronic carriers than in HCC patients
(48.8 vs. 24.5%, P=0.006; Table 2). Compared with
chronic carriers, HCC patients had a signiﬁcantly
higher frequency of BCP T1762/A1764 mutants (77.7
vs. 21.2%, P=0.0001; Table 3), and a higher frequency
of PC A1896 mutants (46.0 vs. 30.2%, P=0.04).
We next analysed for the presence of combinations
of either PC wild type or A1896 mutant sequences and
BCP wild type or T1762/A1764 mutant sequences in
the HCC patients and chronic carriers. As can be seen
in Figure 1, there were signiﬁcantly more PC wild-type
sequences plus BCP wild-type sequences in the
chronic carriers than that in the HCC patients. Also,
compared with chroniccarriers, higher numbers of PC
wild-type sequences plus BCP T1762/A1764 mutant
sequences (44.7 vs. 12.8%), and more PC A1896
mutant sequences plus BCP T1762/A1764 mutant
sequences were detected in HCC patients (32.9 vs.
8.5%, P=0.001 for all observations).
The mean baseline serum HBV DNA values in the
HCC patients were signiﬁcantly higher compared with
chronic carriers who were preselected to have serum
Table 1. Baseline characteristics of hepatitis B surface antigen-positive chronic carriers and hepatocellular carcinoma patients
Chronic carriers HCC patients P value
Number of patients 67 101
Age (mean) 45.412.3 years 53.313.5 years 0.002
Male 29 (43.3%) 84 (83.2%) o0.0001
Asian 58 (86.6%) 91 (90.1%) 0.35
Alkaline phosphatase
(mean)
66.550.2U/L 201.3288.3U/L o0.0001
Albumin (mean) 4.40.4mg/dL 3.70.7mg/dL o0.0001
AST (mean) 18.711.4U/L 128.8142.6U/L o0.0001
ALT (mean) 19.913.8U/L 92.999.4U/L o0.0001
Total bilirubin (mean) 0.520.23mg/dL 1.72.6mg/dL o0.0001
Platelets (mean) 221.694.510
3/mm
3 203.8149.210
3/mm
3 0.37
AFP (median) 0.39 (minimum 0, maximum 0.9)
log10ng/mL
2.15 (minimum 0, maximum 6.25)
log10ng/mL
0.0001
AFP (mean) 0.390.18 log10ng/mL 2.441.55 log10ng/mL 0.0001
AFP, a-foetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma.
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5copies/mL (Po0.0001;
Table 2). However, over 50% of the HCC patients also
had HBV DNA levels of  10
5copies/mL (Table 3). In
98 HCC patients tested, 29 (29.6%) were HBeAg
positive, 68 (69.4%) were anti-HBe positive and one
(1%) was both HBeAg positive and anti-HBe positive.
By preselection, all 67 chronic carriers were HBeAg
negative and anti-HBe positive.
By univariate analysis, older age (P=0.002), male
gender (P=0.001), HBV genotype C (P=0.0003), PC
A1896 mutants (P=0.04) and BCP T1762/A1764
mutants (P=0.0001) were signiﬁcantly associated
with HCC (Table 3).
Logistic regression models
The HBV genotype was not detectable in 33 patients,
and another nine patients did not have measurable
BCP sequences. Thus, a total of 126 patients had
complete data for HBV molecular markers. Logistic
regression analysis was conducted utilizing unrest-
ricted (n=168) and restricted (n=126) data sets to
determine the sensitivityof HBV molecular markers as
risk factors for HCC, and both models yielded similar
results. Next, logistic regression analysis was con-
ducted with partially adjusted models (age, gender
and race) and with a model fully adjusted for all the
Table 3. Demographic and virologic characteristics of hepatitis B virus chronic carriers and patients with hepatocellular carcinoma
Characteristics
Chronic carriers Patients with HCC
P value OR (95% CI)w n=67 n=101
Age 45.412.3 SD years 53.313.5 SD years 0.002 1.05 (1.02–1.08)
Gender
Female 38 (56.7%) 17 (17.0%) 0.0001 1
Male 29 (43.3%) 84 (83.0%) 6.47 (3.18–13.18)
Asian
No 9 (13.4%) 9 (8.9%) 0.35 1
Yes 58 (86.6%) 92 (91.1%) 1.59 (0.59–4.23)
HBV genotype C
No 27 (65.8%) 30 (31.9%) 0.0003 1
Yes 14 (34.2%) 64 (68.1%) 4.11 (1.89–8.95)
PC
Wild type 44 (69.8%) 54 (54.0%) 0.04 1
A1896 mutant 19 (30.2%) 46 (46.0%) 1.97 (1.01–3.84)
BCP
Wild type 37 (78.7%) 21 (22.3%) 0.0001 1
T1762/A1764 mutant 10 (21.2%) 73 (77.7%) 12.86 (5.49–30.11)
HBV load
 10
5copies/mL 67 (100.0%) 63 (51.5%) 0.0001 NA
410
5copies/mL 0 (0.0%) 38 (48.5%)
Data are provided as n (%) or meanSD.
wWhen n (%) is provided, the P value and OR (95% CI) is reported from w
2 tests or Fisher’s exact test. In case of meanSD, the P value is reported from
t-tests and OR (95% CI) is reported from univariate logistic regression.
BCP, basal corepromoter;CI, conﬁdence interval; HBV, hepatitis Bvirus; HCC, hepatocellularcarcinoma; NA, not applicable;OR, odds ratio; PC, precore;
SD, standard deviation.
Table 2. Baseline virologic markers in hepatitis B surface antigen-positive chronic carriers and hepatocellular carcinoma patients
Chronic carriers HCC patients P value
HBV genotype
A 4/ 41 (9.8%) 4/ 93 (4.3%) NS
B 20/41 (48.8%) 23/93 (24.7%) 0.02
C 13/41 (31.7%) 62/93 (66.7%) 0.02
A1B 0/ 41 (0.0%) 1/ 93 (1.1%) NS
B1C 1/ 41 (2.4%) 2/ 93 (2.1%) NS
D 3/ 41 (7.3%) 1/ 93 (1.1%) NS
HBV DNA (mean) 2.561.99 log10copies/mL 5.971.63 log10copies/mL o0.0001
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NS, not signiﬁcant.
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mutation, BCP T1762/A1764 mutation). The latter
was the best predictor model because it had the lowest
AIC (106.3). Thus, utilizing the fully adjusted model,
we found that the BCP T1762/A1764 mutation was
independently associated with HCC development [OR
11.14, 95% conﬁdence interval (CI) 3.05–40.72;
Po0.001; Table 4]. In addition, the PC A1896 muta-
tion was also associated with a higher risk for devel-
oping HCC (OR 3.75, 95% CI 1.14–12.34; Po0.05).
However, the HBV genotype was not an independent
predictor for HCC.
Follow-up
During a mean follow-up period of 112.177.7 SD
months, none of the 67 chronic carriers had progres-
sion of liver disease or developed HCC. In the 101
patients with HCC, nine received liver transplantation,
19 had liver resection, 24 had transarterial chemoem-
bolization, six had percutaneous ethanol injection,
three had radiofrequency ablation and 42 patients
received no therapy. Only nine HCC patients are still
alive at this time, but three have recurrence of HCC.
Discussion
The average age of our HBsAg-positive HCC patients
at presentation was 53 years and is similar to HCC
patients from China, Taiwan and Japan (3, 7, 12). Also,
83% of our HCC patients were male, which also is
observed worldwide (1). This is in contrast to our
chronic carriers in which over 50% were female.
Although the mean age of our chronic carriers was
41.2 years on presentation, their average age was 50
years at last follow-up, which is close to the mean age
of our HCC patients at their ﬁrst clinic visit. During
the average 112 months of follow-up, none of the
chronic carriers had progressive liver disease or devel-
oped HCC, suggesting that their prognosis is excellent
(23). If this is the case, these chronic carriers may not
require antiviral treatment. However, the incidence of
HCC occurrence in chronic carriers is estimated to be
0.1%, and so annual surveillance for HCC is still
recommended (24). In our previous report, all labora-
tory parameters of liverfunction in HCC patients were
abnormal, but none of these tests was able to distin-
guish HCC patients from those with HBV-related
cirrhosis (16).
Previous studies have indicated that high circulating
HBV DNA levels are predictive for liver disease
progression. In an 11-year follow-up study of 3582
Chinese patients, a high viral load at entry was
associated with progression to cirrhosis (25). Also, we
recently reported that cirrhosis patients with elevated
HBV DNA levels had a higher probability of death
from non-HCC-related liver complications than those
with low HBV DNA values (26). High-circulating
HBV DNA levels were also predictive for HCC devel-
opment (3, 13, 15). In a report from Taiwan, the
cumulative incidence rate for HCC was 1.3% in
patients with baseline HBV DNA levels of o300
copies/mL compared with a 14.9% incidence rate in
patients with Z10
6copies/mL (15). In the latter study,
patients with persistent HBV DNA elevations during
59.6%
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Fig. 1. Analysis of precore and basal core promoter wild types
and mutants in chronic carriers and hepatocellular carcinoma
(HCC) patients.
Table 4. Multivariate analysis of viral factors associated with
the development of hepatocellular carcinoma
OR (95% CI) P value
HBV genotype C
No 1
Yes 3.28 (0.89–12.13) o0.10
PC A1896 mutation
No 1
Yes 3.75 (1.14–12.34) o0.05
BCP T1762/A1764 mutation
No 1
Yes 11.14 (3.05–40.72) o0.001
Analyses restricted to 126 subjects (HCC=90, chronic carriers=36)
who had complete tests on HBV genotype (genotype C), PC and BCP
genes. The multivariate model was adjusted for age, gender and race.
BCP, basal core promoter; CI, conﬁdence interval; HBV, hepatitis B virus;
HCC, hepatocellular carcinoma; OR, odds ratio; PC, precore.
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study, we preselected an HBV DNA level of  10
5
copies/mL in the chronic carriers, and none of these
patients had liver disease progression or developed
HCC. However, 51% of our HCC patients presented
with HBV DNA levels of  10
5copies/mL. Because
we preselected the HBV DNA level in the deﬁnition of
our chronic carriers, we were unable to make mean-
ingful comparisons with the HCC patients.
The mutation from G to A in the PC region at
nucleotide 1896 was described in patients with
HBeAg-negative chronic hepatitis (6, 27). This PC
A1896 mutation creates a stop codon that prevents
translation of the PC protein and abolishes the pro-
duction of HBeAg. However, these patients continue
to synthesize HBV DNA at sufﬁcient levels to cause
continual liver damage with progression to cirrhosis
(21). The frequency of PC mutants has been reported
to be similar in patients with HCC and in inactive
carriers, and some authors even suggested that acqui-
sition of PC mutants may actually lead to inactivation
of the chronic liver disease state (5, 28). In our study,
the presence of PC mutants alone was detected in
30.2% of the chronic carriers and 46% of the HCC
patients(P=0.04).Also, 33%of our HCCpatientshad
both PC A1896 and BCPA1762/T1764 mutants, while
15% of the HCC patients had PC A1896 mutants and
BCP A1762/T1764 wild-type sequences (Fig. 1). This
observation suggests that the BCPA1762/T1764 muta-
tion may be the principal driving force for the devel-
opment of HCC, and the PC A1896 mutants also play
a signiﬁcant, albeit lesser, role in the progression to
HCC. Up until the present, PC A1896 mutants have
not been implicated in HCC development. To further
clarify the role of PC A1896 mutants in HCC develop-
ment, future studies should include other viral factors
such as genotypes and BCP A1762/T1764 mutants as
possible confounding factors.
The BCP T1762/A1764 mutations were detected in
HCC patients from Asia and Africa. A study from
Guangxi Autonomous Region in China showed that
close to 100% of HCC patients tested had BCP T1762/
A1764 mutants in both serum and tumour tissue (3).
Another report from Taiwan showed that 71% of HCC
patients had BCP T1762/A1764 mutants (5). The
prevalence of BCP T1762/A1764 in African patients
with HCC was 66% compared with only 11% in
asymptomatic carriers (4). Recently, we reported that
the presence of genetic mutations in the BCP and PC
regions in cirrhosis patients was predictive for HCC
development (26). Other studies identiﬁed the role of
BCP mutants with high HBV DNA levels in hepato-
carcinogenesis (29, 30). In the present study, BCP
T1762/A1764 mutants alone or in combination with
PC A1896 mutants were detected in 45 and 33% of our
HCC patients respectively. Our ﬁndings emphasize the
important role of the BCP T1762/A1764 mutants in
the pathogenesis of HCC.
Close to 90% of our chronic carriers and HCC
patients were Asian, which determined the predomi-
nant HBV genotypes detected in this study. Genotype
B was found in 48% of the chronic carriers compared
with 25% of the HCC patients. In contrast, 67% of our
HCC patients had genotype C while only 32% of the
chronic carriers had this genotype. The presence of
HBV genotype C has been associated with the devel-
opment of HCC in Asia (9, 10, 31, 32). A study from
Shanghai, China, showed that 98% of HCC patients
had genotype C (32). In Taiwan, genotype C was
associated with older HCC patients, while genotype B
was more frequent in young adults and children with
HCC (7, 8) However, in Japan, genotype B was more
common in older patients with HCC (11, 12). In these
latter two reports, HCC patients also had lower rates
of HBeAg positivity and lower levels of HBV DNA.
Another study from Taiwan showed that genotype C
and higher HBV DNA levels were additional risk
factors for HCC (14). In addition, HCC patients with
either genotype C or genotype B who had BCP
mutants and high HBV DNA values were at a higher
risk for HCC irrespective of the presence of PC
mutants (5, 29, 30). More recently, the presence of
T1635 mutation in box a in genotype C patients
increased the HCC risk (33). In another study com-
paring HBV-infected patients with and without HCC,
a proline to serine change in codon 38 that encodesthe
transactivator hepatitis B X protein was associated
with the development of HCC (34). In our present
report, the HBV genotype was not determined to be a
signiﬁcant risk factor by a logistic regression analysis
model adjusted for age, sex, race, genotype, PC muta-
tion and BCP mutation. However, genotype C was
found to be a positive confounding factor in the
relationship between HCC and BCP mutant (i.e. not
adjusting for genotype C, OR for BCP mutants was
16.8, vs. adjusting for genotype C, OR 11.4). In
addition, genotype C was found to be a negative
confounding factor in the relationship between HCC
and PC mutants (i.e. not adjusting for genotype C, OR
for PC mutants was 2.52, vs. adjusting for genotype C,
OR 3.75).
The presence of HBeAg was reported to predict the
development of HCC. In a recent study from Taiwan,
the relative risk of HCC was 9.6 in men who were
initially positive for HBsAg alone, but was 60.2 among
men who were positive for both HBsAg and HBeAg
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at initial recruitment for the study but were not
subsequently measured at the time of HCC occur-
rence. In previous studies, the prevalence rate of
HBeAg positivity in patients with hepatitis B-related
HCC only was 29% in Taiwan, 13% in South Africa
and 15% in the USA (36–38). In these reports, the
anti-HBe-positive prevalence rates were 61, 60 and
61% respectively. In our 101 patients with HCC, 70%
were anti-HBe positive. In our recent natural history
study of 400 HBsAg-positive patients, HBeAg did not
appear to have a pathogenetic role in HCC develop-
ment (26).
The limitations of our study include a single base-
line measurement for HBV DNA in both the chronic
carriers and in HCC patients. It is well known that
ﬂuctuations in serum HBV DNA occur during the
course of chronic hepatitis B infection, especially
during the exacerbation phases of the disease (39).
Also, liver biopsies were not performed in the chronic
carriers. However, during a mean 112-month follow-
up, these latter patients continued to have normal liver
tests and none had liver disease progression. We are
continuing to observe these chronic carriers.
In summary, the BCP A1762/T1764 mutation, fol-
lowed by the PC A1896 mutation had strong correla-
tions with HCC development. Antiviral treatment in
these patients before HCC development is warranted
in an attempt to delay or prevent the appearance of
this lethal malignancy.
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